Compare BHP Billiton Limited (BHP) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs Zimmer Biomet Holdings Inc — how do they compare? BHP Billiton Limited trades at $90.67 (market cap $229.15B), while Zimmer Biomet Holdings Inc trades at $95.26 (market cap $18.55B). The key difference: BHP Billiton Limited is far larger — about 12.4× Zimmer Biomet Holdings Inc's market cap, and BHP Billiton Limited pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| BHP | ZBH | |
|---|---|---|
Market Cap | $229.15B | $18.55B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $107.71 |
52-Week Low | $52.14 | $79.58 |
Enterprise Value | $243.35B | $25.61B |
Dividend Yield | 2.95% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.61, up 0.22% with a bullish technical signal supported by moving averages. The company reported mixed Q4 2025 earnings, missing EPS estimates but maintaining strong profitability with 18.97% net margins. Recent operational challenges include strikes at Port Hedland iron ore operations, while copper production declines in Chile. Valuation metrics show a P/E of 22.36 and P/B of 4.54, reflecting premium pricing relative to historical levels.
The outlook remains cautiously optimistic with analyst consensus leaning hold (64.52%) amid labor disputes and production volatility. Key opportunities include exposure to AI-driven copper demand growth, while risks center on strike impacts and fluctuating commodity prices. The stock's current technical strength faces fundamental headwinds from operational disruptions.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
